Evaluation of clinical efficiency of Decap replacement therapy in patients with type 2 diabetes mellitus and concomitant nonalcoholic fatty liver disease in vitamin D deficiency





Decap, vitamin D deficiency, type 2 diabetes mellitus, nonalcoholic fatty liver disease, insulin resistance, obesity


Background. Recently, vitamin D deficiency has been considered one of the factors in the development of type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). The purpose was to establish the effectiveness of Decap (cholecalcife­rol) in patients with its deficiency who suffered from type 2 DM and NAFLD. Materials and methods. Fifty-two people with NAFLD and type 2 DM on the background of established D-deficiency were treated, they were evenly divided into two groups. Patients in the comparison group (n = 26) received only traditional antidiabetic therapy, and the main group (n = 26) additio­nally took vitamin D — Decap, which was prescribed at a dose of 4,000 IU/day for 6 months. Results. Vitamin D use was associated with a statistically significant reduction in fasting blood glucose after 6 months of treatment — by 4.2 % (p = 0.041). The level of glycated hemoglobin in the main group of patients decreased on ave­rage by 0.38 % (p = 0.121) after 3 months, and remained almost at the same level after 6 months — by 0.44 % (p = 0.088). In parallel with the improvement of glycemic control parameters in the main group, there was a tendency to a decrease in the HOMA-2-IR by 0.28 (–0.11; 0.86; p = 0.152) and to a better insulin sensitivity by 1.39 (–10.04; 6.01; p = 0.621) compared to the baseline. The use of vitamin D (Decap) is associated with a decrease in steatosis indices FLI and TyG. The baseline values for FLI was 74.11 ± 18.71 and for TyG — 5.21 ± 0.29, and after a six-month course of vitamin D treatment, they decreased by 4.4 % (p = 0.029) and 2.68 % (p = 0.031), respectively, compared to baseline. Conclusions. It was found that the use of Decap in patients with vitamin D deficiency at a dose of 4,000 IU/day for a course of at least six months improved glycemic control and metabolic profile in those with type 2 DM and NAFLD.


Download data is not yet available.


Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015 Jun 25;6(6):850-67. doi: 10.4239/wjd.v6.i6.850.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001.

Eslami M, Bahar A, Hemati M, et al. Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders. Diabet Med. 2020 Oct 6:e14415. doi: 10.1111/dme.14415.

Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014 Jan;2(1):56-64. doi: 10.1016/S2213-8587(13)70112-8.

Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016 Oct;12(10):616-22. doi: 10.1038/nrendo.2016.105.

Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017 Jun;5(6):423-430. doi: 10.1016/S2213-8587(17)30097-9.

Rafiq S, Jeppesen PB. Is Hypovitaminosis D Related to Incidence of Type 2 Diabetes and High Fasting Glucose Level in Healthy Subjects: A Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2018 Jan 10;10(1):59. doi: 10.3390/nu10010059.

Panda DK, Miao D, Tremblay ML, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7498-503. doi: 10.1073/pnas.131029498.

Aludwan M, Kobyliak N, Abenavoli L, et al. Hepatic steatosis indices as predictors of vitamin D 3 deficiency in patients with NAFLD associated with type 2 diabetes. Clinical Diabetology. 2020;9(5):313-320. doi: 10.5603/DK.2020.0036.

Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant. 2010 Sep;25(9):2850-65. doi: 10.1093/ndt/gfq313.

Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013 Jul;88(7):720-55. doi: 10.1016/j.mayocp.2013.05.011.

Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385.

American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.

Abdel-Wareth L, Haq A, Turner A, et al. Total vitamin D assay comparison of the Roche Diagnostics "Vitamin D total" electrochemiluminescence protein binding assay with the Chromsystems HPLC method in a population with both D2 and D3 forms of vitamin D. Nutrients. 2013 Mar 22;5(3):971-80. doi: 10.3390/nu5030971.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. doi: 10.1007/BF00280883.

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 Jun;27(6):1487-95. doi: 10.2337/diacare.27.6.1487.

Salazar J, Bermúdez V, Calvo M, et al. Optimal cutoff for the evaluation of insulin resistance through triglyceride-glucose index: A cross-sectional study in a Venezuelan population. F1000Res. 2017 Aug 7;6:1337. doi: 10.12688/f1000research.12170.3.

Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33. doi: 10.1186/1471-230X-6-33.

Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010 Jul;42(7):503-8. doi: 10.1016/j.dld.2009.08.002.

Angellotti E, D'Alessio D, Dawson-Hughes B, et al. Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. J Endocr Soc. 2018 Feb 26;2(4):310-321. doi: 10.1210/js.2018-00015.

Gagnon C, Daly RM, Carpentier A, Lu ZX, Shore-Lorenti C, Sikaris K, Jean S, Ebeling PR. Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial. PLoS One. 2014 Oct 9;9(10):e109607. doi: 10.1371/journal.pone.0109607.

Dabbaghmanesh MH, Danafar F, Eshraghian A, Omrani GR. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial. Diabetes Metab Syndr. 2018 Jul;12(4):513-517. doi: 10.1016/j.dsx.2018.03.006.

Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Ramezani-Jolfaie N, Joukar F. The Efficacy of Vitamin D Supplementation against Nonalcoholic Fatty Liver Disease: A Meta-Analysis. J Diet Suppl. 2020;17(4):467-485. doi: 10.1080/19390211.2019.1624671.

Barchetta I, Del Ben M, Angelico F, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y.



How to Cite

Аludwan М., Kobyliak, N., Pavlenko, G., & Komisarenko, Y. (2021). Evaluation of clinical efficiency of Decap replacement therapy in patients with type 2 diabetes mellitus and concomitant nonalcoholic fatty liver disease in vitamin D deficiency. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 16(8), 607–615. https://doi.org/10.22141/2224-0721.16.8.2020.222881



Original Researches

Most read articles by the same author(s)